Finch Therapeutics Group Analysis
Finch Therapeutics Group is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Finch Therapeutics pink sheet analysis is to determine its intrinsic value, which is an estimate of what Finch Therapeutics Group is worth, separate from its market price. There are two main types of Finch Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Finch Therapeutics pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Finch Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Finch |
Finch Pink Sheet Analysis Notes
About 53.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.14. Some equities with similar Price to Book (P/B) outperform the market in the long run. Finch Therapeutics recorded a loss per share of 6.59. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 12th of June 2023. Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 189 people.The quote for Finch Therapeutics Group is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Finch Therapeutics Group call Mark Smith at 617 229 6499 or check out https://www.finchtherapeutics.com.Finch Therapeutics Investment Alerts
| Finch Therapeutics is not yet fully synchronised with the market data | |
| Finch Therapeutics has some characteristics of a very speculative penny stock | |
| Finch Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 107 K. Net Loss for the year was (74.75 M) with loss before overhead, payroll, taxes, and interest of (57.03 M). | |
| Finch Therapeutics Group currently holds about 104.67 M in cash with (31.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19. | |
| Roughly 53.0% of the company shares are held by company insiders |
Finch Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Finch Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Finch Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Finch Therapeutics's market, we take the total number of its shares issued and multiply it by Finch Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Finch Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Finch Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Finch Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Finch Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Smisek Jeffery A over six months ago Disposition of 3750 shares by Smisek Jeffery A of Finch Therapeutics subject to Rule 16b-3 | ||
Graf Susan E over six months ago Acquisition by Graf Susan E of 44843 shares of Finch Therapeutics subject to Rule 16b-3 | ||
Smisek Jeffery A over six months ago Disposition of 6642 shares by Smisek Jeffery A of Finch Therapeutics at 2.57 subject to Rule 16b-3 | ||
Smisek Jeffery A over a year ago Sale by Smisek Jeffery A of 1470 shares of Finch Therapeutics | ||
Blischak Matthew P over a year ago Acquisition by Blischak Matthew P of 962899 shares of Finch Therapeutics subject to Rule 16b-3 | ||
Blaustein Marc over a year ago Sale by Blaustein Marc of 4619 shares of Finch Therapeutics |
Finch Therapeutics Outstanding Bonds
Finch Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Finch Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Finch bonds can be classified according to their maturity, which is the date when Finch Therapeutics Group has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Finch Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Sectors Now
SectorsList of equity sectors categorizing publicly traded companies based on their primary business activities |
| All Next | Launch Module |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |